Clinical Trials and Research

Recommendations outline best practices for diagnosing rare, complex bone marrow disorder(WASHINGTON — Jan. 28, 2026) — The American Society of Hematology (ASH)…

HistoryThe subtype of TTR protein mutation, its tissue distribution, and the amount of amyloid deposition largely determine the clinical manifestations of ATTR. The…

An amyloidosis diagnosis brings a rush of questions. Where should I go? Who truly understands this disease? Are there clinical trials for someone like me? For too…

Accurate differentiation between light-chain (AL) amyloidosis and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is critical for effective patient…

Northfield, Ill. (November 24, 2025) — A new evidence-based guideline to help standardize the diagnosis of amyloidosis and improve patient care, was just published…

DelveInsight’s “AL Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the AL Amyloidosis, historical…

Data presented at the 2024 American Heart Association (AHA) Scientific Sessions highlighted that early initiation and continuous use of acoramidis (Attruby;…

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased…

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the New York Yankees rallying to win the…

Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM), BridgeBio Pharma announced.…